What Navinci Diagnostics does

Navinci Diagnostics AB is a privately held Swedish biotech company headquartered in Uppsala that develops proprietary in situ proximity ligation assay (isPLA) kits and reagents under the Naveni® brand for spatial proteomics research. The company's technology uses antibody-oligonucleotide conjugates (Navenibodies) that generate amplifiable DNA signals only when two target proteins are in close proximity, enabling detection of protein-protein interactions, post-translational modifications, and single protein localization directly in cultured cells, fresh-frozen tissue, and FFPE samples while preserving native spatial context — a capability that traditional methods such as co-immunoprecipitation and Western blot cannot provide. Its product portfolio spans flexible kits (NaveniFlex, NaveniBright) usable with researchers' own primary antibodies, target-specific kits (PD1/PD-L1, CD8/MHC-I), the NaveniPlex 3-plex platform, BOND RX/RXm-automated kits for high-throughput workflows, the recently launched Omni 9-plex kit, and the Glysite Explorer co-developed with Vector Laboratories for protein glycosylation research.

Navinci sells its products primarily through a direct e-commerce storefront (order.navinci.se) with an Omni Panel Builder for custom configurations, complemented by an international distributor network and CRO Service Partners; the company also offers a full-service laboratory option for researchers who prefer outsourced experimentation. Pricing is published in Swedish Krona and ranges from approximately SEK 3,500 for control kits to SEK 29,500 for automated BOND RX kits, with custom Omni panels quoted on a per-project basis, generating one-time-purchase consumable revenue plus service-based revenue. The customer base is global across EMEA, North America, and Asia Pacific, consisting primarily of academic and translational life science researchers, immuno-oncology investigators, pharmaceutical/biotech drug discovery teams, and academic core facilities such as SciLifeLab; named adopters include Harvard Medical School, Providence Genomics, IFOM, and the University of Palermo.

The company was founded in 2004 and remains privately held, having closed a SEK 90 million Series A in July 2022 led by Segulah Medical Acceleration. In FY2025 Navinci reported sales revenue of SEK 18.1m (up 72% year-over-year, or 86% on a constant-currency basis) with a gross margin of approximately 74.6% and a still-significant EBIT loss of SEK -37.4m, as the business invests in commercial scaling under a newly completed management team and the April 2026 launch of its Omni multiplex platform.

Name

Navinci Diagnostics

Legal name

Navinci Diagnostics AB

Website

https://navinci.se

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

Navinci Diagnostics is a Swedish biotech company developing proprietary in situ proximity ligation assay (isPLA) kits for spatial proteomics. It sells Naveni® reagent kits and the Omni multiplex platform to academic researchers, immuno-oncology investigators, and pharmaceutical drug-discovery teams worldwide.

Ownership category

akta.pro rank

Product category

Spatial Proteomics Reagents

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)

akta.pro secondary industry

Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF)

Keywords

• Spatial proteomics reagents
• Proximity ligation assays
• Protein interaction detection
• Research reagent kits
• Tissue-based assays

Headquarters

HQ city

Uppsala

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Research kits and reagents: Navinci sells proprietary in situ proximity ligation assay kits including flexible kits (NaveniFlex, NaveniBright), target-specific kits (PD1/PD-L1, CD8/MHC-I), and multiplex platforms (Naveni Plex, Omni). Products are sold directly and through distributors globally. Prices range from approximately 3,500 SEK to 29,500 SEK for standard kits, with custom Omni panels quote-based.
2. Custom service offerings: Omni is available as both a ready-to-use kit for in-house experiments and a full-service offering performed by Navinci experts, providing service-based revenue alongside product sales.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

Navinci develops and commercializes proprietary in situ proximity ligation assay (isPLA) reagent kits for detecting proteins, protein-protein interactions, and post-translational modifications directly within tissue and cell samples, preserving spatial context. The product portfolio includes flexible kits (NaveniFlex, NaveniBright), target-specific kits (PD1/PD-L1, CD8/MHC-I), multiplex kits (Naveni Plex, Omni), and glycosylation detection kits (Glysite Explorer), sold to life science researchers globally.

Differentiator

Problem solved

Functional benefit

Brands

• Naveni®: Proprietary in situ proximity ligation assay technology platform and product line including NaveniFlex, NaveniBright, NaveniPlex, and related kits
• Omni
• NaveniFlex
• NaveniBright
• NaveniPlex
• Glysite™ Explorer
• NaveniTriFlex
• NaveniDetect

Products and services

• NaveniFlex kits Flexible in situ proximity ligation assay kits that allow researchers to use one or two of their own primary IgG antibodies combined with Navenibodies for secondary detection. Available in cell and tissue formats with fluorescent readouts (Atto647N, Red/TEX615) for proteins, protein-protein interactions, or modifications in cultured cells, fresh-frozen, and FFPE samples. Prices range from 16,000 to 16,500 SEK.
• NaveniBright kits Chromogenic in situ proximity ligation assay detection kits using HRP substrate for visualization of proteins, protein-protein interactions, or modifications. Priced at 18,500 SEK, suitable for use with standard brightfield microscopy workflows on FFPE, fresh-frozen, and cultured cell samples.
• Naveni Plex First multiplex in situ proximity ligation assay with fluorescent readout, enabling simultaneous detection of 3 separate targets or protein-protein interactions with enhanced specificity and sensitivity. Validated on FFPE human tissue samples with combinations such as PD1/PD-L1, PD1/PD-L2, PD1/SHP-2, CD8/MHC-I, and CD3.
• Omni multiplex kit Next-generation multiplex in situ proximity ligation assay enabling simultaneous detection of up to 9 protein-protein interactions, post-translational modifications, or single protein targets in a single experiment with fluorescent readout. Built on proprietary isPLA technology and available as a ready-to-use customized kit or as a full-service offering performed by Navinci experts. Configured through the Omni Panel Builder with quote-based pricing.
• Glysite Explorer First commercially available kit to study protein glycosylation with spatial context, integrating Vector Laboratories' Glysite Explorer lectins with Navinci's proprietary in situ proximity ligation assay technology. Detects glycans proximal to proteins in tissue samples. Jointly developed with Vector Laboratories and recognized with the CiteAb Innovation Award (Highly Commended) in 2026.
• Naveni Detect + Interact (NaveniTriFlex) Proximity-based in situ kit that concurrently visualizes two proteins in free and complex state using three-channel fluorescent readout, detecting total protein A, total protein B, and interaction AB simultaneously. Priced at 22,500 SEK for use with mouse and rabbit primary antibodies to study functional states and protein interplay.
• Naveni PD1/PD-L1 target-specific kits Target-specific kits for detecting PD1/PD-L1 interactions in situ with high signal-to-noise ratio. Available in NaveniBright chromogenic (HRP), Atto647N fluorescent, and BOND RX automated versions. First commercial assay for detecting PD1/PD-L1 interaction in situ, used in immunotherapy research and patient stratification studies. Prices range from 18,500 to 29,500 SEK.
• Naveni CD8/MHC-I kit Target-specific in situ proximity ligation assay kit for detecting CD8/MHC-I interactions, offering novel insights into T-cell engagement and antigen recognition for immune cell dynamics research. Used by Providence Genomics and academic researchers in immunology and immuno-oncology.
• Naveni BOND RX automated kits Automated proximity ligation assay kits optimized for the Leica BOND RX and RXm Fully Automated Research Stainer, with pre-optimized protocols enabling high-throughput processing. Includes chromogenic (NaveniBright HRP, 29,500 SEK for PD1/PD-L1) and other readout formats designed for immediate application on BOND RX/RXm instruments.
• Naveni Control Kit Control kit used for validating proximity ligation assay signals when running NaveniFlex and NaveniBright kits. Priced at 3,500 SEK.
• NaveniLink kit Conjugation kit for creating custom Navenibodies (antibody-oligonucleotide conjugates) with user-provided primary antibodies. Priced at 11,500 SEK, enables researchers to expand the isPLA platform to additional targets of interest.
• Omni full-service offering Full-service offering for the Omni multiplex kit where Navinci experts perform the experiment on behalf of the customer. Enables researchers without in-house capability to access multiplex spatial interactomics experiments performed by Navinci's scientific team.

Quantifiable outcome

• 72% year-over-year sales growth in 2025 (86% adjusted for currency)
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

AI capability3 records

Feature8 records

Partnerships

Seven partnerships are on record, tiered core and supporting.

• Uppsala UniversitycoreStrategic or Co-development Partner · 7 April 2026Collaboration as part of the SIXP (Spatial Interactomics with Cell Painting) project to develop next-generation technology platform for mapping cellular signaling and drug responses. Uppsala contributes leading expertise in molecular interaction biology and drug discovery. Joint work includes proof-of-concept studies for Omni technology.
• SciLifeLabcoreStrategic or Co-development Partner · 7 April 2026Collaboration in the SIXP project providing advanced high content imaging, screening capabilities and data infrastructure. Once established, technology will be implemented within CBCS infrastructure at SciLifeLab enabling national research access.
• Chemical Biology Consortium Sweden (CBCS)coreStrategic or Co-development Partner · 7 April 2026Part of SIXP collaboration; provides screening infrastructure and will host the technology platform for researcher access across Sweden supporting drug discovery, systems biology, and precision medicine applications.
• Pixl BiosupportingTechnology or Integration · 7 April 2026Provides advanced image analysis and AI-based tools for spatial data interpretation as part of the SIXP collaboration.
• Vector LaboratoriescoreStrategic or Co-development Partner · 17 March 2026Joint development of Glysite Explorer kit, integrating Vector's Glysite Explorer lectins with Navinci's proprietary in situ PLA technology for studying protein glycosylation. Won CiteAb Innovation Award 2026. Product adopted by leading research institutions worldwide.
• Leica BiosystemssupportingTechnology or IntegrationBOND RX/RXm compatibility - Navinci has developed automated proximity ligation assay kits optimized for Leica BOND RX/RXm Fully Automated Research Stainer, enabling high-throughput processing.
• Harvard Medical School (Barthel and Schatton laboratories)supportingStrategic or Co-development PartnerCollaborative research using Glysite Explorer for studying protein glycosylation in tumor microenvironment; presented findings at NextGen Omics and AACR 2026 conferences.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Rebus Biosystems: Emerging U.S. spatial omics company with the STELLARIS platform for highly multiplexed spatial transcriptomics. Competes in the same translational research market but with a narrower technology scope focused on RNA rather than protein-protein interactions.

Others

• Bio-Techne: Large U.S. life sciences reagents company (including R&D Systems, ProteinSimple, and Advanced Cell Diagnostics) selling antibodies, ELISA kits, and spatial biology reagents. Indirectly comparable as a broad proteomics reagent supplier that researchers may substitute or bundle against Navenci's specialty kits.
• Vector Laboratories: U.S. immunohistochemistry reagent supplier and Navinci's co-development partner on Glysite Explorer. Adjacent rather than competitive — provides lectin reagents and IHC consumables that Navinci integrates into its isPLA kits.

Broad incumbents

• Standard BioTools: Former Fluidigm; commercializes the Hyperion imaging mass cytometry platform for highly multiplexed spatial proteomics in tissue. Competes for spatial-proteomics core facility budgets with a broader, more capital-intensive instrument-based offering.
• 10x Genomics: U.S. leader in single-cell and spatial biology with the Xenium in situ platform (RNA plus emerging protein assays), Visium, and Chromium product lines. Overlaps with Navinci in spatial tissue analysis but addresses a much broader multi-omics portfolio with substantially larger commercial reach.
• NanoString Technologies (a Bruker company): Spatial biology platforms including CosMx SMI (single-cell spatial molecular imaging) and GeoMx DSP for digital spatial profiling. Larger incumbent with broader spatial transcriptomics and proteomics coverage than Navinci's protein-interaction focus.

Direct peers

• Olink: Swedish protein biomarker company using Proximity Extension Assay (PEA), a dual-recognition proximity-based technology closely analogous to Navinci's isPLA. Most directly comparable peer by origin (Sweden/Uppsala) and underlying proximity-detection chemistry, though Olink operates in soluble protein biomarkers rather than in situ tissue.
• Lunaphore: Swiss spatial biology company commercializing the COMET multiplex sequential immunofluorescence platform for tissue proteomics. Directly comparable to Navinci's NaveniFlex/NaveniBright and Omni kits as a competing approach to high-multiplex spatial protein detection in FFPE tissue.
• Akoya Biosciences: U.S. spatial biology company offering the PhenoCycler (formerly CODEX) platform and OPAL multiplex immunohistochemistry reagents for tissue-based multiplex proteomics. Competes with Navinci for the same translational and academic research budget for spatial protein analysis in tissue.
• Cell Signaling Technology (CST): Major U.S. antibody and reagent supplier that also markets proximity ligation assay (PLA) kits and IHC reagents. Directly competes with Naveni product lines at the bench-reagent level while also offering the broader antibody portfolio and assay support that researchers often consolidate on.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Navinci Diagnostics